We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Relistor CRL May Trigger More Safety Concerns With Constipation Drugs
Relistor CRL May Trigger More Safety Concerns With Constipation Drugs
August 15, 2012
The FDA’s recent complete response letter (CRL) on Salix’s sNDA for opioid-induced constipation (OIC) drug Relistor most likely cites safety concerns and signals increased scrutiny for all makers of these drugs, analysts say.